Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.52 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elisartan SCHEMBL29595840 | 1.00 | AGTR1 (0.52) | AGTR1AGTR2PPARGKCNH2 | |
| Elisartan SCHEMBL489081 | 0.99 | AGTR1 (0.53) | AGTR1AGTR2PPARGKCNH2 | |
| Elisartan SCHEMBL489079 | 0.99 | AGTR1 (0.53) | AGTR1AGTR2PPARGKCNH2 | |
| Elisartan SCHEMBL1560942 | 0.99 | AGTR1 (0.52) | AGTR1AGTR2PPARGKCNH2 | |
| Elisartan SCHEMBL615370 | 0.99 | AGTR1 (0.52) | AGTR1AGTR2PPARGKCNH2 | |
| SCHEMBL12990879 | 0.93 | AGTR2 (0.53) | AGTR1AGTR2PPARG | |
| SCHEMBL6130076 | 0.92 | AGTR1 (0.48) | AGTR1AGTR2 | |
| SCHEMBL4609266 | 0.92 | AGTR1 (0.48) | AGTR1AGTR2 | |
| SCHEMBL12991717 | 0.91 | AGTR2 (0.51) | AGTR1AGTR2 | |
| SCHEMBL13771416 | 0.90 | AGTR1 (0.48) | AGTR1AGTR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389105-A4 | METHOD OF TREATMENT | MERCK & CO INC (US) | 2005-08-17 | — | — | EP | claimed |
| EP-1389105-A1 | METHOD OF TREATMENT | Merck & Co., Inc. (US) | 2004-02-18 | — | — | EP | claimed |
| US-20030073705-A1 | Method of treatment | SHAHINFAR SHAHNAZ (US) | 2003-04-17 | — | — | US | claimed |
| WO-2002092081-A1 | METHOD OF TREATMENT | MERCK & CO., INC. (US) | 2002-11-21 | — | — | WO | claimed |
| US-6300356-B1 | ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST | MERCK & CO., INC. | 2001-10-09 | — | — | US | claimed |
| US-6201002-B1 | ADMINISTERING IMIDAZOLE DERIVATIVE TO TREAT CONGESTIVE HEART FAILURE AND CARDIOVASCULAR DISORDERS | MERCK & CO., INC. | 2001-03-13 | — | — | US | claimed |
| EP-3241839-B1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL, INFLAMMATION, CANCER AND OTHER DISORDERS | BAUSCH HEALTH IRELAND LTD (IE) | 2019-09-04 | — | — | EP | disclosed |
| EP-3239170-B1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | SYNERGY PHARMACEUTICALS INC (US) | 2019-03-20 | — | — | EP | disclosed |
| EP-3366698-A1 | GUANYLATE CYCLASE C AGONISTS | Synergy Pharmaceuticals Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9920095-B2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| EP-2810951-B1 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20160367623-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | SYNERGY PHARMACEUTICALS INC. | 2016-12-22 | — | — | US | disclosed |
| US-20160243188-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | JPMORGAN CHASE BANK, N.A. | 2016-08-25 | — | — | US | disclosed |
| EP-1635773-A2 | COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION | Merck & Co., Inc. (a New Jersey corp.) (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1389105-A4 | METHOD OF TREATMENT | MERCK & CO INC (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004110368-A2 | COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION | MERCK & CO., INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040116510-A1 | Antihypertensive agent and cholesterol absorption inhibitor combination therapy | NICHTBERGER STEVEN A (US) | 2004-06-17 | — | — | US | disclosed |
| EP-1389105-A1 | METHOD OF TREATMENT | Merck & Co., Inc. (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030073705-A1 | Method of treatment | SHAHINFAR SHAHNAZ (US) | 2003-04-17 | — | — | US | disclosed |
| WO-2002092081-A1 | METHOD OF TREATMENT | MERCK & CO., INC. (US) | 2002-11-21 | — | — | WO | disclosed |